Anti-VEGF Receptor 2 (phospho Y1175) antibody (ab38464)
- Product nameAnti-VEGF Receptor 2 (phospho Y1175) antibodySee all VEGF Receptor 2 primary antibodies ...
- DescriptionRabbit polyclonal to VEGF Receptor 2 (phospho Y1175)
- SpecificityThis antibody is specific for VEGF Receptor 2 only when phosphorylated at Tyrosine 1175. Customer feedback suggests the antibody does not work in rat or mouse tissue.
- Tested applicationsIHC-P, ELISA more details
- Species reactivityReacts with: Human
Does not react withMouse, Rat
Synthetic phosphopeptide derived from Human VEGF Receptor 2 around the phosphorylation site of tyrosine 1175.
- Positive controlBreast carcinoma tissue slides.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
- Concentration information loading...
- PurityImmunogen affinity purified
- Purification notesThe antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
- Clonality Polyclonal
Our Abpromise guarantee covers the use of ab38464 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||IHC-P: Use at an assay dependent dilution.|
- FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
- Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
- Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Cellular localizationMembrane.
- CD309 antibodyCD309 antigen antibodyFetal liver kinase 1 antibody
- FLK-1 antibodyFLK1 antibodyKDR antibodyKinase insert domain receptor (a type III receptor tyrosine kinase) antibodyKinase insert domain receptor antibodyKRD1 antibodyLy73 antibodyProtein tyrosine kinase receptor FLK1 antibodyProtein-tyrosine kinase receptor flk-1 antibodyTyrosine kinase growth factor receptor antibodyVascular endothelial growth factor receptor 2 antibodyVEGFR 2 antibodyVEGFR antibodyVEGFR-2 antibodyVEGFR2 antibodyVGFR2_HUMAN antibody
Anti-VEGF Receptor 2 (phospho Y1175) antibody images
ab38464 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using immunohistochemistry, Paraffin Embedded Tissue.
Left image : untreated.
Right image : treated with phosphopeptide.
References for Anti-VEGF Receptor 2 (phospho Y1175) antibody (ab38464)
ab38464 has not yet been referenced specifically in any publications.